399 related articles for article (PubMed ID: 23351639)
1. Increased levels of interleukins 8 and 10 as findings of canine inflammatory mammary cancer.
de Andrés PJ; Illera JC; Cáceres S; Díez L; Pérez-Alenza MD; Peña L
Vet Immunol Immunopathol; 2013 Apr; 152(3-4):245-51. PubMed ID: 23351639
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-8 as a prognostic serum marker in canine mammary gland neoplasias.
Gelaleti GB; Jardim BV; Leonel C; Moschetta MG; Zuccari DA
Vet Immunol Immunopathol; 2012 Apr; 146(2):106-12. PubMed ID: 22405680
[TBL] [Abstract][Full Text] [Related]
3. Steroids and receptors in canine mammary cancer.
Illera JC; Pérez-Alenza MD; Nieto A; Jiménez MA; Silvan G; Dunner S; Peña L
Steroids; 2006 Jul; 71(7):541-8. PubMed ID: 16631217
[TBL] [Abstract][Full Text] [Related]
4. Histological, immunohistological, and ultrastructural description of vasculogenic mimicry in canine mammary cancer.
Clemente M; Pérez-Alenza MD; Illera JC; Peña L
Vet Pathol; 2010 Mar; 47(2):265-74. PubMed ID: 20106772
[TBL] [Abstract][Full Text] [Related]
5. Metastasis of canine inflammatory versus non-inflammatory mammary tumours.
Clemente M; Pérez-Alenza MD; Peña L
J Comp Pathol; 2010; 143(2-3):157-63. PubMed ID: 20427049
[TBL] [Abstract][Full Text] [Related]
6. Different role of COX-2 and angiogenesis in canine inflammatory and non-inflammatory mammary cancer.
Clemente M; Sánchez-Archidona AR; Sardón D; Díez L; Martín-Ruiz A; Caceres S; Sassi F; Dolores Pérez-Alenza M; Illera JC; Dunner S; Peña L
Vet J; 2013 Aug; 197(2):427-32. PubMed ID: 23489848
[TBL] [Abstract][Full Text] [Related]
7. Cox-2 levels in canine mammary tumors, including inflammatory mammary carcinoma: clinicopathological features and prognostic significance.
Queiroga FL; Perez-Alenza MD; Silvan G; Peña L; Lopes C; Illera JC
Anticancer Res; 2005; 25(6B):4269-75. PubMed ID: 16309227
[TBL] [Abstract][Full Text] [Related]
8. Establishment and characterization of a canine xenograft model of inflammatory mammary carcinoma.
Camacho L; Peña L; González Gil A; Cáceres S; Díez L; Illera JC
Res Vet Sci; 2013 Dec; 95(3):1068-75. PubMed ID: 23972378
[TBL] [Abstract][Full Text] [Related]
9. Expression of vascular endothelial growth factor in canine inflammatory and non-inflammatory mammary carcinoma.
Millanta F; Caneschi V; Ressel L; Citi S; Poli A
J Comp Pathol; 2010 Jan; 142(1):36-42. PubMed ID: 19632688
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical vascular factor expression in canine inflammatory mammary carcinoma.
Camacho L; Peña L; Gil AG; Martín-Ruiz A; Dunner S; Illera JC
Vet Pathol; 2014 Jul; 51(4):737-48. PubMed ID: 24048323
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of C5a receptor (CD88) mRNA in canine mammary tumors.
Hezmee MN; Kyaw-Tanner M; Lee JY; Shiels IA; Rolfe B; Woodruff T; Mills PC
Vet Immunol Immunopathol; 2011 Jan; 139(1):50-6. PubMed ID: 20846729
[TBL] [Abstract][Full Text] [Related]
12. First description of feline inflammatory mammary carcinoma: clinicopathological and immunohistochemical characteristics of three cases.
Pérez-Alenza MD; Jiménez A; Nieto AI; Peña L
Breast Cancer Res; 2004; 6(4):R300-7. PubMed ID: 15217496
[TBL] [Abstract][Full Text] [Related]
13. The Expression of Selected Factors Related to T Lymphocyte Activity in Canine Mammary Tumors.
Bujak JK; Szopa IM; Pingwara R; Kruczyk O; Krzemińska N; Mucha J; Majchrzak-Kuligowska K
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32225066
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical Expression of CCR2, CSF1R and MMP9 in Canine Inflammatory Mammary Carcinomas.
Raposo TP; Beirão BC; Pires I; Prada J; Brilhante P; Argyle DJ; Queiroga FL
Anticancer Res; 2016 Apr; 36(4):1805-13. PubMed ID: 27069163
[TBL] [Abstract][Full Text] [Related]
15. Role of steroid hormones and prolactin in canine mammary cancer.
Queiroga FL; Pérez-Alenza MD; Silvan G; Peña L; Lopes C; Illera JC
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):181-7. PubMed ID: 15862964
[TBL] [Abstract][Full Text] [Related]
16. Profile of Steroid Receptors and Increased Aromatase Immunoexpression in Canine Inflammatory Mammary Cancer as a Potential Therapeutic Target.
De Andrés PJ; Cáceres S; Clemente M; Pérez-Alenza MD; Illera JC; Peña L
Reprod Domest Anim; 2016 Apr; 51(2):269-75. PubMed ID: 26899138
[TBL] [Abstract][Full Text] [Related]
17. Steroid pathway and oestrone sulphate production in canine inflammatory mammary carcinoma.
Sánchez-Archidona AR; Jiménez MA; Pérez-Alenza D; Silván G; Illera JC; Peña L; Dunner S
J Steroid Biochem Mol Biol; 2007 May; 104(3-5):93-9. PubMed ID: 17466517
[TBL] [Abstract][Full Text] [Related]
18. Development, anatomy, histology, lymphatic drainage, clinical features, and cell differentiation markers of canine mammary gland neoplasms.
Sorenmo KU; Rasotto R; Zappulli V; Goldschmidt MH
Vet Pathol; 2011 Jan; 48(1):85-97. PubMed ID: 21147765
[TBL] [Abstract][Full Text] [Related]
19. Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence.
Sorenmo KU; Kristiansen VM; Cofone MA; Shofer FS; Breen AM; Langeland M; Mongil CM; Grondahl AM; Teige J; Goldschmidt MH
Vet Comp Oncol; 2009 Sep; 7(3):162-72. PubMed ID: 19691645
[TBL] [Abstract][Full Text] [Related]
20. Expression of the oncogene c-erbB-2 in canine mammary cancers and tumor-derived cell lines.
Ahern TE; Bird RC; Bird AE; Wolfe LG
Am J Vet Res; 1996 May; 57(5):693-6. PubMed ID: 8723884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
